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The Integrin avb6 Binds and Activates Latent TGFb1:
A Mechanism for Regulating Pulmonary
Inflammation and Fibrosis
functions in vivo are due at least in part to differences
in the promoter regions of the various isoform genes
(Taipale et al., 1998). It is also possible, but not proven,
that there are TGFb isoform±specific mechanisms for
converting latent TGFbs to the active forms.
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The mechanisms involved in activating latent TGFb
are not fully understood, but recently there has beenTransforming growth factor b (TGFb) family members
important progress in this area. Plasmin can activateare secreted in inactive complexes with a latency-
latent TGFb in cell-free systems (Lyons et al., 1990) andassociated peptide (LAP), a protein derived from the
in cell culture (Sato et al., 1990). However, plasminogenN-terminal region of the TGFb gene product. Extracel-
knockout mice display none of the pathologic featureslular activation of these complexes is a critical but
of TGFb knockout mice, suggesting that plasmin is un-incompletely understood step in regulation of TGFb
likely to be the only molecule activating TGFb. Reactivefunction in vivo. We show that TGFb1 LAP is a ligand
oxygen species can activate TGFb in vitro (Barcellos-for the integrin avb6 and that avb6-expressing cells
Hoff and Dix, 1996), and radiation treatment appearsinduce spatially restricted activation of TGFb1. This
able to activate TGFb in vivo via this mechanism (Bar-finding explains why mice lacking this integrin develop
cellos-Hoff et al., 1994). Thrombospondin (TSP) 1 canexaggerated inflammation and, as we show, are pro-
activate TGFb by binding to a defined site on LAP andtected from pulmonary fibrosis. These data identify a
inducing a conformational change in the latent complex;novel mechanism for locally regulating TGFb1 function
TGFb is then bound to TSP1 in an active state (Schultz-in vivo by regulating expression of the avb6 integrin.
Cherry and Murphy-Ullrich, 1993; Schultz-Cherry et al.,
1995). A recent study of the similar patterns of inflam-
Introduction
mation exhibited by TGFb1 and TSP1 knockout mice
suggests that TSP1 is a major activator of TGFb1 in
The transforming growth factor b (TGFb) family consists
vivo (Crawford et al., 1998). However, the inflammatory
of three closely related isoforms (TGFb1, -2, and -3)
changes in the TSP1 knockout mice are not nearly as
that are prototypes of the larger TGFb superfamily. In severe as those in TGFb1 knockout mice, suggesting
vitro, TGFbs exert nearly identical effects that can be overlapping mechanisms of TGFb activation.
grouped into three broad areas: modulation of inflam- LAP-b1 and LAP-b3 contain arginine-glycine-aspartic
matory cell function, growth inhibition and differen- acid (RGD) sequences, which are also binding site motifs
tiation, and control of extracellular matrix production. in ligands for a subset of integrins. LAP-b1 can bind
Studies of animal models as well as human clinical spec- effectively to one such integrin, avb1, but the functional
imens strongly suggest that TGFbs are important in the role of LAP±integrin interactions is not known (Munger
pathogenesis of several diseases, including fibrotic con- et al., 1998). Integrins were first identified based on their
ditions (Broekelmann et al., 1991; Border et al., 1992; roles in mediating cell attachment and migration but
Sime et al., 1997). TGFb1 knockout mice develop diffuse have recently been recognized to participate in more
mononuclear cell infiltrates that prove lethal within a few complex cellular events, including survival (Meredith et
weeks from birth (Shull et al., 1992; Kulkarni et al., 1993). al., 1993), proliferation, and regulation of gene expres-
In contrast, TGFb2 and TGFb3 knockout mice display sion (Werb et al., 1989). The fact that avb1 can bind
only developmental defects (Kaartinen et al., 1995; San- latent TGFb suggests that this or other RGD-binding
ford et al., 1997). Major differences among TGFb isoform integrins might regulate TGFb bioactivity.
The integrin avb6 is expressed principally on epithelial
cells, where it has been shown to be a receptor for RGD7 To whom correspondence should be addressed (e-mail: deans@
sites in fibronectin (Weinacker et al., 1994), tenascinitsa.ucsf.edu).
8 These authors contributed equally to this work. (Prieto et al., 1993), and vitronectin (Huang et al., 1998a).
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avb6 is expressed at low levels in healthy adult lung
tissues but is rapidly upregulated by injury and inflam-
mation (Breuss et al., 1995). Inactivation of the b6 sub-
unit gene in mice revealed an unexpected role for avb6
in downregulating inflammatory responses to minor en-
vironmental insults in the lungs and skin (Huang et al.,
1996). Somewhat surprisingly, despite exaggerated skin
and lung inflammation, b62/2 mice do not develop fibro-
sis at either site. The combination of enhanced inflam-
mation and protection from fibrosis suggested a local-
ized deficiency of active TGFb1 as a cause of the b62/2
phenotype. We therefore sought to determine whether
TGFb1 LAP is a ligand for avb6 and whether interaction
of avb6 with LAP-containing complexes can lead to
latent TGFb1 activation. To determine whether such an
effect might have relevance to disease, we also utilized
b62/2 mice in a well-characterized model of pulmonary
fibrosis induced by bleomycin, a model that has pre-
viously been shown to be critically dependent on TGFb
(Giri et al., 1993).
Results
TGFb1 LAP Is a Ligand for the Integrin avb6
To determine whether LAP-b1 could bind avb6, we per-
formed affinity chromatography by passing labeled se-
Figure 1. Affinity Chromatographycreted avb6 over Sepharose cross-linked to recombi-
(A) 35S-labeled secreted avb6 was incubated with either BSA-, fi-nant LAP, the known avb6 ligand fibronectin, or bovine
bronectin- or LAP-Sepharose. Bound proteins were eluted withserum albumin (BSA; to detect nonspecific binding).
EDTA and analyzed by SDS-PAGE under nonreducing conditions.Bound proteins were eluted by EDTA, since interactions
Lane 1 was the final fraction eluted with column buffer, lanes 2±6
of integrins with ligands require the presence of divalent were eluted with EDTA, and lane 7 was eluted with 8 M urea.
cations. Bands corresponding to truncated av (130 kDa) (B) Western blot of eluted fractions with anti-b6 antibody 4B5. Lane
and b6 (85 kDa) were eluted by EDTA from LAP- or 1 was the final fraction eluted with column buffer, lanes 2±4 were
eluted with EDTA, and lane 5 was eluted with 8 M urea.fibronectin-Sepharose, but not from BSA-Sepharose
(C) Immunoprecipitation of CHO supernatant (lane 1) and CHO su-(Figure 1A). The identity of the 85 kDa band as b6 was
pernatant proteins eluted by EDTA from BSA (lane 2) and LAP (laneconfirmed by Western blotting and by immunoprecipita-
3) columns with anti-avb6 MAb R6G9.
tion (Figures 1B and 1C). To demonstrate that full-length (D) Western blot of proteins from octylglucoside lysates of b6-trans-
avb6 also binds to LAP, we repeated affinity chromatog- fected SW480 cells eluted from BSA- or LAP-Sepharose columns.
raphy with unlabeled octylglucoside lysates of b6-trans- Lane 1 was the final fraction eluted with column buffer, lanes 2±5
were eluted with EDTA, and lane 6 was eluted with 8 M urea. Molecu-fected SW480 cells (Figure 1D). A 95 kDa protein corre-
lar size markers (in kDa) are shown to the left.sponding to full-length b6 was detected by Western
blotting in eluted fractions from LAP-Sepharose but not
from BSA-Sepharose.
not mock-transfected, SW480 cells to either LAP orTo determine the effects of avb6/LAP interactions on
equimolar concentrations of either small or large latentcells, we performed cell adhesion assays with b6-trans-
TGFb1 complexes containing LAP induced phosphory-fected SW480 cells. LAP-coated wells supported avb6-
lation of two downstream integrin-signaling intermedi-dependent adhesion of b6-transfected cells, but mock-
ates, the focal adhesion kinase (FAK) and paxillin (Figuretransfected cells did not adhere to any concentration
2E). Phosphorylation of each protein was completelyof LAP (Figure 2B). Essentially identical results were
inhibited by addition of the avb6-blocking antibodyobtained with mock- and b6-transfected 293 cells, Chi-
10D5 (not shown).nese hamster ovary (CHO) cells, and NIH 3T3 cells (not
shown). b6-transfected SW480 cells, but not mock
b6-Transfected Cells Induce TGFb Activitytransfectants, also adhered to dishes coated with large
To determine if binding to avb6 activates TGFb1, welatent TGFb1 complexes (LLC; Figure 2C). Adhesion to
cocultured four different b6-expressing cells with minkLAP and LLC was abolished by anti-avb6 antibody 10D5
lung epithelial reporter cells stably expressing a portionand was unaffected by antibodies against b1 (P5D2) or
of the plasminogen activator inhibitor 1 promoter (TMLC)avb5 (P1F6; not shown). To determine whether avb6
(Abe et al., 1994). For all four lines, coculture with b6-mediated adhesion to LAP through an interaction with
expressing cells caused a significant increase in lucifer-the RGD sequence, we performed cell adhesion assays
ase levels compared to coculture with control cells (Fig-with mutant LAP containing a D-to-E substitution muta-
ure 3A). These increases were abolished by MAbstion within the RGD site (Figure 2D). b6-transfected
against active TGFb or avb6. A different reporter cell lineSW480 cells did not attach to any concentration of mu-
tant LAP. Furthermore, adhesion of b6-transfected, but (NIH 3T3 cells transfected with PAI1/luciferase) yielded
Integrin-Induced TGFb Activation
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Figure 2. Adhesion of b6-Transfected Cells
to LAP
(A) Control and b6-transfected SW480 cells
were stained with anti-avb6 mAB E7P6 (white
peaks represent control cells; black peaks
represent b6 transfectants) and analyzed by
flow cytometry. Dotted lines represent b6-
transfected cells incubated with PBS.
(B and C) Nontransfected cells and b6-trans-
fected cells were allowed to attach to wells
coated with increasing concentrations of LAP
(B) or LLC (C) or with 1% BSA. Prior to plating,
cells were incubated with or without anti-
avb6 antibody 10D5.
(D) Adhesion of SW480-b6 cells to recombi-
nant LAP containing a single glutamic acid
for aspartic acid substitution mutation in the
RGD site (RGE LAP) was compared with ad-
hesion to authentic recombinant LAP.
(E) Lysates of mock- and b6-transfected SW480
cells plated for 30 min on poly-L-lysine (PLL)
or on poly-L-lysine plus fibronectin (Fn), LAP,
SLC, or LLC were immunoprecipitated with
antibodies against FAK or paxillin followed
by Western blotting with either anti-phospho-
tyrosine antibody 4G10, anti-FAK, or anti-
paxillin.
similar results (data not shown). Three cell lines that are presented, so latent TGFb secreted by the cocultured
cells is sufficient for measurable TGFb activation. Tocapable of adhering to immobilized LAP via avb1 (293,
MG63, and A549 cells) (Munger et al., 1998) did not determine whether the observed active TGFb was spe-
cifically TGFb1, we added isoform-specific neutralizingactivate TGFb in similar assays (Figure 3A and unpub-
lished data). Antibodies against the integrin b1 subunit antibodies against TGFb1, b2, and b3 to cocultures con-
taining b6-transfected SW480 cells. Anti-TGFb1 blockedor the integrin avb5 had no effect on activation (not
shown). luciferase induction, whereas anti-TGFb2 and anti-TGFb3
did not (Figure 3C). In addition, recombinant LAP (whichTo determine whether TGFb activation by avb6 re-
quired cell±cell contact, we did coculture assays with both neutralizes TGFb in solution and binds the avb6
integrin) blocked TGFb activation.inserts to separate reporter and b6-expressing cells by
a few millimeters while allowing soluble molecules to
pass. In the absence of contact, b6-expressing cells
caused a slight induction of luciferase activity, but in- avb6-Mediated Activation of TGFb1 Does
Not Require Other Knownduction was minimal compared to b6-expressing cells in
contact with the reporter cells (Figure 3B). These results Activators of TGFb
We next tested whether avb6-induced activation ofindicate that the active TGFb generated by avb6 is most
efficiently detected by cells in contact with the b6- TGFb1 was occurring through previously described
mechanisms of TGFb activation. Activation of TGFb byexpressing cells, but that at least a small amount of the
active TGFb formed is freely diffusible. cocultures of endothelial cells and vascular smooth
muscle requires plasmin (Sato et al., 1990), binding ofTo determine if increased secretion of latent TGFb
by b6-expressing lines could account for the results, mannose-6-phosphate on LAP (Dennis and Rifkin, 1991),
and incorporation of LLC into the ECM via tissue trans-serum-free medium conditioned by each line was tested
for total TGFb activity. b6-transfected CHO cells se- glutaminase (Kojima et al., 1993; Nunes et al., 1997).
Therefore, we tested the effects of inhibitors that blockcreted more latent TGFb (8-fold) than did mock-trans-
fected CHO cells. However, in the other three cell types, each of these steps: the plasmin inhibitor aprotinin, M6P,
inhibitors of transglutaminase-mediated cross-linkinglatent TGFb secretion was higher in the control lines
(data not shown). All four lines secreted TGFb1 as the (cystamine and monodansylcadaverine), and a poly-
clonal antibody against the N terminus of LTBP1 (Ab450)predominant TGFb isoform. Cocultures in serum-free
conditions yielded results essentially identical to those that blocks LTBP linkage to the ECM (Nunes et al., 1997).
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Figure 3. b6-Expressing Cells Activate TGFb
(A) Equal numbers of reporter and test cells
were cultured 16±20 hr and lysed for mea-
surement of luciferase activity. Results are
for four test cell lines. Additions are shown
at the bottom (anti-TGFb: MAb 1D11, 10 mg/
ml; anti-b6: MAb 10D5, 10 mg/ml). Relative
luciferase activity is the measured activity di-
vided by the activity of the coculture with
mock-transfected cells. Results are the mean
(6SEM) of at least three experiments done in
duplicate.
(B) The effect of close proximity between re-
porter and test cells on TGFb activation was
determined using culture inserts. Equal num-
bers of reporter cells in the bottom well, test
cells in the bottom well, and test cells in the
insert were cocultured for 16±20 hr and lucif-
erase activity of the reporter cells was mea-
sured. Relative luciferase activity is measured
activity divided by the activity of reporter cells
cultured with control cells in both the bottom
well and the insert. Results are the means
(6SEM) of triplicate measurements.
(C) Activation of TGFb by b6-expressing cells
does not require the activity of proteases or
molecules involved in other systems of TGFb
activation and involves only TGFb isoform 1.
Mock- or b6-transfected SW480 cells were
cocultured with reporter cells as described in
(3A). Additions are indicated at the bottom.
Data represent the mean (6SEM) of quadru-
plicate measurements.
Because other proteases can activate TGFb in vitro Binding of LAP to avb6 Integrin Is Not Sufficient
for Latent TGFb1 Activation(Munger et al., 1998), we tested inhibitors of metallo-,
aspartic, and cysteine proteases (BB94, BB2516, leu- To determine whether binding to avb6 is sufficient for
activation of TGFb or whether additional interactionspeptin, pepstatin A, and E64). Finally, TSP1-mediated
activation of TGFb1 can be blocked by MAb 133 (Schultz- with cell components are required, we examined the
effects of truncation mutations of the b6 subunit cyto-Cherry et al., 1994). None of these inhibitors blocked
the activation observed in cocultures with b6-express- plasmic domain. Three mutants were examined; of
these, only mutant 777T, which lacks the last 11 aminoing cells (Figure 3C).
Integrin-Induced TGFb Activation
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Figure 4. Binding of LAP to avb6 Integrin Is
Not Sufficient for Latent TGFb Activation
(A) Schematic representation of the wild-type
b6 integrin subunit (full-length b6) and the
three truncation mutants studied.
(B) Mock- or various b6-transfectants were
incubated in suspension with 0.1 mg/ml LAP
for 30 min at 378C and analyzed by flow cy-
tometry with anti-LAP MAb VB3A9. Relative
fluorescence is the mean fluorescence of
each sample divided by the mean fluores-
cence of mock transfectants. Results are the
mean (6SEM) of at least three experiments.
(C) Equal numbers of reporter and test cells
were cultured for 16±20 hr and luciferase ac-
tivity was measured. For (C±E), relative lucif-
erase activity is the measured activity divided
by the activity of the TMLC alone and results
are the mean (6SEM) of at least three experi-
ments done in duplicate.
(D) TMLC were cultured for 16±20 hr in the
presence or absence of cytochalasin D (100
mm), human recombinant TGFb1 (10 pM), or
anti-TGFb (MAb 1D11, 10 mg/ml).
(E) Equal numbers of reporter cells and test
cells were cultured for 16±20 hr in the pres-
ence or absence of cytochalasin D (100 mm),
anti-avb6 integrin (MAb 1OD5, 50 mg/ml), or
anti-TGFb (MAb 1D11, 10 mg/ml).
acids of the b6 cytoplasmic domain, localizes to focal the ability of reporter cells to respond to active TGFb
added to the culture medium (Figure 4D). However, cyto-contacts (Cone et al., 1994). To determine whether dele-
tions in the b6 cytoplasmic domain would affect latent chalasin D added to cocultures of b6 transfectants and
reporter cells blocked activation of latent TGFb (FigureTGFb1 binding, transfectants were incubated with LAP
and analyzed by flow cytometry with antibody to LAP. 4E). The inhibition was similar to that achieved by anti-
body to avb6 or to TGFb. Thus, an intact cytoskeletonMore LAP was detected on the surface of cells express-
ing wild-type avb6 than on mock transfectants (Figure is required for avb6-mediated activation of TGFb.
4B). Mutant 747T showed no binding above background,
but both 770T and 777T showed LAP binding similar to b62/2 Mice Are Protected against Bleomycin-Induced
Pulmonary Fibrosiswild-type avb6. In coculture assays, cells expressing
mutants 747T and 770T showed little or no activation Pulmonary fibrosis was evaluated by examination of
lung morphology and by measurement of hydroxypro-of latent TGFb (Figure 4C). In contrast, mutant 777T
activated latent TGFb. No consistent difference was de- line content in b61/1 and b62/2 129 strain mice at 15, 30,
and 60 days after intratracheal instillation of bleomycin.tected in total TGFb secreted by these transfectants
(data not shown). Since 770T bound LAP but failed to Fibrosis was significant in bleomycin-treated wild-type
mice by 30 days and progressed to 60 days (Figureactivate latent TGFb, binding of LAP by avb6 is not
sufficient for activation of latent TGFb. 5A), whereas in b62/2 mice, lung morphology remained
nearly unaltered throughout the experiment, with onlyTo determine whether an intact cytoskeleton is re-
quired for TGFb activation, we cocultured reporter cells small patches of fibrosis (Figure 5B), and the lung hy-
droxyproline content was not significantly different fromwith b6-transfected SW480 cells in the presence of 100
mm cytochalasin D, conditions under which 100 percent that measured in saline-treated animals. Similar results
were obtained in offspring of 129 by C57Bl/6 inter-of the cells became round but remained adherent. Cyto-
chalasin D did not inhibit LAP binding to the cell surface, crosses (not shown). These results suggest that expres-
sion of avb6 is required for pulmonary fibrosis in re-nor did it affect surface expression of avb6 or TGFb
secretion (not shown). Cytochalasin D had no effect on sponse to bleomycin.
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antibody. TGFb eluted from lung slices was not different
between lines or between saline and bleomycin treat-
ment (relative luciferase activity compared to TMLC
alone): saline, 6.5 6 1.6 (mean 6 SEM) for b61/1 mice
and 6.3 6 1.4 for b62/2 mice; bleomycin, 5.5 6 1.6 for
b61/1 mice and 5.2 6 1.1 for b62/2 mice. Furthermore,
immunohistochemistry with an antibody against a 30-
amino-acid C-terminal peptide of TGFb1 (LC1-30) under
conditions reported to detect both active and inactive
TGFb (Barcellos-Hoff et al., 1995) revealed the presence
of TGFb throughout the lungs and airways in both saline-
and bleomycin-treated animals, with no detectable in-
crease at any time point after bleomycin treatment in
either line of mice. Immunohistochemistry under condi-
tions reported to detect only active TGFb demonstrated
little staining at any time point (data not shown).
avb6 Protein Expression Is Focally Induced
by Bleomycin in b61/1 Mice
We have previously reported that avb6 is expressed at
low levels in skin and lung epithelium, but that expres-
sion is dramatically upregulated in cutaneous wounds
and in injured and inflamed epithelia (Breuss et al., 1995).
To determine whether bleomycin treatment produced
similar increases in avb6 expression, we performed im-
munohistochemistry on lung sections from b61/1 mice
10 days after treatment with either saline or bleomycin.
As expected, no avb6 immunoreactivity was seen in
Figure 5. b62/2 Mice Are Protected against Bleomycin-Induced Pul-
lungs from b62/2 mice. Diffuse, low-level expression ofmonary Fibrosis
avb6 was apparent in airway and alveolar epithelial cells
(A) Bleomycin (0.03 iu: blm) induces pulmonary fibrosis in b61/1 but
in b61/1 mice treated with saline, whereas focal areasnot b62/2 mice, indicated by an elevation of lung hydroxyproline
with markedly increased expression of avb6 were pres-content compared with saline (sal)-treated controls 30 and 60 days
after administration. Data from saline-treated mice at each time ent throughout the lungs of bleomycin-treated animals
point are combined, as there was no significant difference between (Figure 6A).
groups. Data are expressed as means (6 SEM) of five to seven
observations, ** p , 0.01.
Keratinocytes and Airway Epithelial Cells(B) Histology of low power sections (magnification 2003) demon-
strates dense accumulation of collagenous extracellular matrix in Activate TGFb1 through avb6
lungs of bleomycin-treated b61/1 but not b62/2 mice 60 days after To determine directly whether avb6 expressed in mouse
injection. skin could activate TGFb1, we performed bioassays by
coculturing keratinocytes obtained from b62/2 or b61/1
mice with TMLC (Figure 6C). b61/1 cells expressed abun-To determine whether the resistance of b62/2 mice to
dant amounts of avb6 (Figure 6B) and demonstratedbleomycin-induced lung injury and fibrosis was due to
TGFb1 activity in this assay (Figure 6C), whereas b62/2a blunted inflammatory response, we counted inflamma-
cells did not induce TGFb1 activity. Because of the diffi-tory cells obtained from bronchoalveolar lavage (BAL) or
culty of culturing murine lung epithelial cells, we per-minced lungs from b62/2 and b61/1 mice after treatment
formed similar studies using primary cultures of humanwith saline and 5 and 15 days after treatment with bleo-
bronchial epithelial cells, which also demonstrated sig-mycin. Bleomycin increased the total cell counts and
nificant expression of avb6 (Figure 6B). These cells alsothe numbers of neutrophils, lymphocytes, and macro-
induced avb6-dependent TGFb1 activity.phages in both lines of mice, but the effects were always
greater in b62/2 mice. These findings are consistent with
our previous report of enhanced lung inflammation in Discussion
b62/2 mice and suggest that protection from bleomycin-
induced pulmonary fibrosis is not due to inhibition of In this report, we show that LAP-b1 is a ligand for the
integrin avb6 and that avb6-expressing cell lines canthe inflammatory response to bleomycin.
To determine whether the exaggerated inflammation activate endogenous latent TGFb1. Furthermore, b62/2
mice are protected from bleomycin-induced pulmonaryand protection from injury and fibrosis in b62/2 mice
was due to impaired synthesis of TGFb1, we analyzed fibrosis, a model that has been shown to be critically
dependent on TGFb activity. In the mice we studied,TGFb protein expression by immunohistochemistry and
by the TMLC bioassay on eluates from lung slices that TGFb1 was constitutively expressed in the lungs, and
the amount of total TGFb protein was not demonstrablyhad been heated to 808C for 20 min to release and
activate TGFb. Specificity of the bioassay was con- different in b62/2 and b61/1 mice and was not signifi-
cantly affected by treatment with bleomycin. However,firmed by .80% inhibition of all samples by anti-TGFb1
Integrin-Induced TGFb Activation
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which in turn locally activates TGFb1 already abundantly
present in many tissues. TGFb1, once activated, en-
hances matrix deposition (healing or fibrosis) and down-
regulates the inflammatory response to injury.
This feedback model highlights the fact that resolution
of inflammation is an active process. There are two regu-
latory pathways that might allow rapid amplification of
this antiinflammatory feedback system. First, TGFb itself
induces b6 integrin subunit expression (Sheppard et al.,
1992; Wang et al., 1996). Second, TGFb1 induces its
own expression (Van Obberghen-Schilling et al., 1988).
Presumably, mechanisms exist to reverse these positive
feedback effects; these mechanisms may fail in patho-
logic states of persistent TGFb activity and fibrosis that
involve epithelia.
The b6 knockout mice develop inflammation only in
skin and lung and not in other tissues where b6 is ex-
pressed (e.g., uterus, renal epithelium, urinary bladder).
This selectivity could be a consequence of the unique
susceptibility of the skin and lung to environmental in-
sults, leading to subclinical inflammation that must be
actively repressed. For example, skin involvement oc-
curs in areas most exposed to physical trauma, and
lung inflammation in b62/2 mice is worse when mice are
housed in unventilated cages. However, mice express-
ing a null mutation in the TGFb1 gene develop exagger-
ated inflammation in multiple organs (Shull et al., 1992).
In addition, in keeping with the known effects of TGFb1
in inhibiting proliferation of epithelial cells, these mice
demonstrate increased mitoses and epithelial hyperpla-
sia in multiple epithelial organs. Despite careful morpho-
logic examination of the liver, pancreas, bladder, stom-
ach, uterus, and intestine, we have been unable to
identify any of these abnormalities in b62/2 mice. To-
gether, these data demonstrate that binding to avb6 is
not the principal mechanism of TGFb1 activation in most
organs and that the developmental effects of TGFb1 do
not require activation by interaction with this integrin.
Whereas other activation mechanisms are involved inFigure 6. Bleomycin Focally Increases avb6 Expression in b61/1
developmental effects of TGFb1, interaction with avb6Mice, and Keratinocytes and Airway Epithelial Cells Expressing avb6
appears to be important for locally titrating the aug-Activate TGFb1
mented TGFb1 activity required in response to injury,(A) Representative sections from lungs of b61/1 mice 10 days after
at least in the lungs and skin.treatment with saline or bleomycin. Arrows, normal staining of con-
ducting airway epithelium; arrowheads, alveolar epithelial cells with Previous studies of TGFb activation suggested the
dramatically increased avb6 expression. critical involvement of proteases, particularly plasmin.
(B) Primary cultures of b61/1 and b62/2 keratinocytes or human Our results, along with other recent work, suggest that
bronchial epithelial cells (HBE) were stained with anti-avb6 antibod- nonproteolytic mechanisms are important physiologic
ies 10D5 or E7P6 (shaded histograms) or PBS and analyzed by flow
pathways leading to active TGFb. TSP1-mediated acti-cytometry.
vation occurs when TSP1 binds LAP-b1 at a site near its(C) b61/1 and b62/2 keratinocytes or HBE were cocultured with
N terminus. This presumably induces a conformationalTMLC for 16±20 hr in the presence or absence of anti-avb6 antibody
10D5 or anti-TGFb1 antibody (101). Relative luciferase activity is change that activates the complex, although the active
measured activity divided by activity of TMLC alone. Data are the TGFb1 molecule remains bound to TSP1. avb6 binds
mean (6SEM) of at least four measurements. LAP at the RGD site located near the C terminus. The
nonproteolytic mechanisms must rely on an intrinsic
ability of LAP to adopt different conformations. Confor-
in response to bleomycin, avb6 expression was dramati- mational flexibility of LAP has already been documented
cally increased in the lungs of b61/1 mice. Together with in circular dichroism studies that showed recombinant
the observations that b62/2 mice develop inflammation free LAP undergoing a major conformational change
in the skin and lungs (partially reproducing the TGFb1 upon binding TGFb in solution (McMahon et al., 1996).
knockout phenotype), the results of this study indicate While avb6 expression is clearly necessary for the
that the regulated expression of avb6 by epithelia is TGFb activation mechanism we describe, is it sufficient?
important for local activation of TGFb1 in response to If avb6 is not sufficient, its role might simply be to con-
injury and inflammation. This idea is consistent with a centrate latent TGFb at the cell surface, thereby permit-
ting some separate mechanism to activate TGFb. Inmodel in which tissue injury induces avb6 expression,
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that multiple integrins can bind TGFb1-LAP raises the
possibility of an additional function, the ability to initiate
signaling via integrins. The results of the present study
demonstrate that LAP-containing latent TGFb1 com-
plexes can induce phosphorylation of at least two com-
ponents of integrin-signaling complexes, FAK and paxil-
lin. This finding raises the possibility that these ªlatentº
complexes could initiate integrin-mediated effects on
cell behavior.
The observation that avb6 induces TGFb1 activity also
suggests an alternative mechanism by which at least
one integrin can affect cell behaviorÐby activating ex-
tracellular TGFb1 that, in turn, initiates responses by
binding to its own cognate receptor(s). This mechanism
appears to explain the exaggerated lung and skin inflam-Figure 7. Model of TGFb1 Activation by avb6
mation and protection from pulmonary fibrosis in b62/2The data presented suggest that when latent TGFb1 complexes
mice and suggests the possibility of regulating localbind to avb6, sites in the b6 cytoplasmic domain become accessible
inflammation and fibrosis by targeting this integrin.for binding to the actin cytoskeleton. Cytoskeleton-associated inte-
grin then induces a change in the conformation of the latent com-
plex, allowing access of mature TGFb1 to TGFb receptors and induc-
Experimental Procedurestion of classic TGFb signaling.
Cell Lines, Antibodies, and Reagents
Cell lines were obtained from American Type Culture Collection and
transfected with integrin expression plasmids as described (Wein-attempting to answer this question, we tested whether
acker et al., 1994). Mink lung epithelial cells stably transfected withmolecules or processes known to be involved in other
a plasmid containing the luciferase cDNA downstream of a TGFb-systems of TGFb activation are required. Previous stud-
sensitive portion of the plasminogen activator inhibitor 1 promoteries of endothelial and smooth muscle cell cocultures, (TMLC) were used as described (Abe et al., 1994). Mouse anti-avb6
which activate latent TGFb, suggested that plasmin, MAbs E7P6, R6G9 (Weinacker et al., 1994), and 10D5 (Huang et al.,
the IGF-II/M6PR, and transglutaminase-mediated cross- 1998a), rabbit anti-b6 MAbs 4B5 and B1 (Huang et al., 1998b), and
mouse MAb VB3A9 against TGFb1 LAP (Munger et al., 1998) werelinking of latent TGFb to the ECM are all required for
produced as described. Mouse anti-phosphotyrosine MAb 4G10activation. However, our results indicate that none of
was obtained from Upstate Biotechnology, Inc. (Lake Placid, NY);these molecules or processes, nor TSP1 or a wide range
mouse MAbs against FAK and paxillin were obtained from Transduc-of proteases, is involved in avb6-mediated activation of tion Laboratories (Lexington, KY); and rabbit polyclonal antibodies
TGFb. In addition, the fact that we observe activation against FAK were obtained from Santa Cruz Biotechnology (Santa
using six different avb6-expressing cell lines and two Cruz, CA). LAP and LAP (RGE) were produced in a baculovirus
system as described (Munger et al., 1998). Recombinant SLC andreporter cell lines suggests that any additional mole-
LLC were gifts of Drs. H. Ohashi and H. Tsumura (Kirin Brewery Co.,cules that are required must be widely expressed.
Gunma, Japan). MAb 1D11 against active TGFb (all isoforms), anti-We have identified one additional requirement for acti-
TGFb1 polyclonal chicken Ig (AF-101-NA), anti-TGFb2 polyclonalvation: the ability of avb6 to connect with the actin cy- goat IgG (AB-112-NA), and anti-TGFb3 polyclonal goat IgG (AB-
toskeleton. Cells expressing mutant b6 were able to 244-NA) were from R and D Systems, Minneapolis, MN. Anti-TSP1
activate TGFb only when the mutant integrin could local- MAb 133 (Schultz-Cherry and Murphy-Ullrich, 1993) was a gift of
Dr. Murphy-Ullrich (University of Alabama, Birmingham). Rabbitize to focal contacts, a process that involves clustering
polyclonal antiserum LC1-30 against a C-terminal peptide of TGFb1and mechanical linkage of integrins to the actin cytoskel-
was a gift of Kathy Flanders (National Cancer Institute, Bethesda,eton in complexes containing an array of adapter pro-
MD). Anti-LTBP1 polyclonal rabbit antibody 450 was produced asteins that includes FAK and paxillin. Cells expressing described (Nunes, et al., 1997). Other reagents were all analytical
b6 mutants that do not localize to focal contacts do grade.
not activate latent TGFb, even though one of these b6 Cell lines were grown in Dulbecco's modified Eagle's medium
(DMEM) with 4.5 g/l glucose, L-glutamine, and 10% fetal bovinemutants (770T) is still able to bind LAP via avb6. Cyto-
serum. Murine keratinocytes were obtained and grown as previouslychalasin D, which disrupts actin filaments, blocked
described (Huang et al., 1996). Human bronchial epithelial cells wereTGFb activation by cells expressing avb6. These results
purchased from Clonetics, grown in serum-free bronchial epithelialsuggest that binding of latent TGFb to avb6 per se is cell medium (Clonetics), and used at passage 1.
not sufficient for activation to occur; following binding,
avb6 must also associate with the actin cytoskeleton in
Affinity Chromatographyorder to activate bound latent TGFb (see model, Figure
LAP, BSA, and chymotrypsin-digested fibronectin were coupled to
7). Thus, modulation of cytoskeleton/avb6 interactions cyanogen bromide±activated Sepharose essentially as described
might be a means to regulate TGFb1 activation indepen- (Pytela et al., 1985). Affinity matrices contained 2.5 mg/ml of fibro-
nectin, 4 mg/ml of BSA, and 7 mg/ml of LAP. Columns were washeddent of changes in avb6 expression.
and blocked with 1% BSA. Secreted avb6 was produced as de-Of the integrins known to bind RGD sequences, three
scribed (Weinacker et al., 1994). Culture medium was passedare now known to bind to LAP-b1 (avb1, avb6, and,
through affinity columns, and bound proteins were eluted with col-weakly, avb5), and one, the platelet integrin aIIbb3, may
umn buffer, then with 20 mM EDTA in 50 mM Tris and 150 mM NaCl,
(Grainger et al., 1995). The main functions heretofore and finally with 8 M urea. Octylglucoside lysates of b6-transfected
ascribed to LAP are TGFb latency and the facilitation SW480 cells were used for affinity chromatography under the same
conditions with addition of 25 mM octylglucoside.of TGFb secretion (Gray and Mason, 1990). The finding
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Immunoprecipitation quick frozen in liquid nitrogen. Five micrometer sections were
stained with hematoxylin and eosin and with trichrome to identifySamples were incubated with antibodies for 3 hr at 48C. Immune
complexes were collected by incubation for 1.5 hr with protein extracellular collagen. Sections were fixed in cold acetone for b6
antibody (B1) or in methanol/acetone for ªactiveº TGFb staining withG±Sepharose. Beads were washed three times, boiled for 3 min in
Laemli sample buffer, and then analyzed by SDS-PAGE and autora- antibody (LC1-30). Sections were blocked with Peroxoblock (Zymed
Lab) and Avidin/Biotin Blocking Kit (Vector) and rinsed and incu-diography.
bated with 3% goat serum in PBS for 15 min and then overnight at
48C in primary antibody. Sections were incubated in biotin-labeledWestern Blotting
secondary antibody for 1 hr and in ABC avidin/peroxidase reagentProteins were separated by SDS-PAGE, transferred to a nylon mem-
(Vector Lab) for 1 hr at room temperature, and chromagen wasbrane, and blocked for 1 hr in Tris-buffered saline containing 3%
developed using the DAB Plus Kit (Zymed).BSA or 5% skim milk. After incubation with primary antibody for 3
hr and then with peroxidase-conjugated secondary antibody for 1
hr, blots were developed with ECL (Amersham). Acknowledgments
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